Actelion acquires new thermo-stable PAH drug

Swiss drugmaker Actelion is to acquire an improved, thermostable formulation of intravenous pulmonary arterial hypertension treatment  epoprostenol sodium developed by privately-held US firm GeneraMedix

Actelion will be responsible for worldwide development, registration and  commercialization of the product. Financial details of the agreement  were not disclosed.

The US Food and Drug Administration approved the new formulation for the  long-term intravenous treatment of primary pulmonary hypertension and  pulmonary hypertension associated with the scleroderma spectrum of  disease in June, 2008.